Biotech Values

[DewDiligence]

Wheeler mentioned the lack of 180-day exclusivity for Copaxone because some sell-side analysts are confused about how the process works and erroneously stated in their reports that MNTA’s generic Copaxone was entitled to 180 days of exclusivity.

From a practical standpoint, the issue is irrelevant for the reason you mentioned.